Cartesian Therapeutics (RNAC) jumped over 30% on Tuesday after announcing a licensing deal to develop its CAR-T cell therapies using a drug delivery technology developed by the mRNA therapeutics ...

Shares of Cartesian Therapeutics rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune ...

WestGene’s established targeted LNP platform combined with Cartesian’s mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Highlights of Python 3.15, now available in beta, include lazy imports, faster JITs, better error messages, and smarter profiling. The first full beta of Python 3.15 ...

Just to go ahead and give everyone a quick refresher, CAR-T treatment aims to reengineer a patient’s T-cells so that they will eliminate harmful B-cells that cause all sorts of problems. To this day, ...

Shares of Cartesian Therapeutics rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year. Shares were up 29% to $8.81 in Monday afternoon ...

In his column “Acrademics,” Alexandre Acra ’26 sheds light on the ins and outs of Stanford and Silicon Valley culture. Dear Acrademics, The world around us seems to be losing rigor and specificity by ...

Investors might want to bet on Cartesian Therapeutics, Inc. (RNAC), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...